Skip to content Skip to footer

Tag: dupixent

HomeAll PostsTag: dupixent
Tribe Public CEO Presentation & Q&A: Hosted Friday, August 21 Tribe Public hosted its CEO Presentation and Q&A webinar, “Food Shouldn’t Hurt: EOE, Eupraxia, and a Promising New Treatment Approach,” featuring James Helliwell, MD, Chief Executive Officer of Eupraxia Pharmaceuticals Inc. (NASDAQ:…
For patients with eosinophilic esophagitis, eating can become an exercise in calculated risk rather than a simple pleasure. For Eupraxia Pharmaceuticals Inc. (NASDAQ: EPRX; TSX: EPRX), that burden represents both an urgent medical problem and a potentially compelling opportunity to prove that…
Sanofi’s latest Dupixent win and Eupraxia Pharmaceuticals’ quiet grind in eosinophilic esophagitis (“EoE”) still tell a coherent, investor‑friendly story: the type 2 inflammation boom is alive, and there is room on the highway for both mega‑cap platforms and focused innovators. For investors,…
Eupraxia’s (NASDAQ: EPRX) latest data drop puts eosinophilic esophagitis (EoE) firmly at center stage, with fresh endoscopic and long‑term clinical results suggesting EP‑104GI could emerge as a once‑yearly, procedure‑based alternative to chronic biologic regimens such as Sanofi’s (SNY) multi-billion dollar weekly-injectable drug…